At $12.4 billion, San Diego biotech Samumed is one of the highest-valued healthcare startups in the country. It’s goal? Reverse aging.
Founded in 2008 by now-billionaire Osman Kibar, the company is focused on developing medicines that could (one day) do things like erase wrinkles or cure blindness. The key, Kibar thinks, lies in teaching our cells to regenerate—prompting progenitor stem cells back into action to help repair aging organs.
In August, Samumed raised $438 million in equity funding, a stunning investment for a company that, while promising, still has no approved drugs. To-date, it’s raised more than $650 million.